Not provided
Not provided
Not provided
Not provided
Not provided
Internal company decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to evaluate the long-term safety and tolerability of SAGE-324 in participants with essential tremor (ET).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SAGE-324 60 mg | Experimental | Participants will receive SAGE-324 15 milligrams (mg) from Day 1 to Day 14, followed by up-titration to 30 mg from Day 15 to Day 28, then to 45 mg from Day 29 to Day 42, and then 60 mg starting on Day 43, orally, once daily. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SAGE-324 | Drug | SAGE-324 oral tablets |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) | An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the first dose of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study. | Up to 814 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements: Heart Rate, Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) | Number of participants with PCS postbaseline vital sign values are summarized for categories: supine and standing (1 and 3 minutes [min]) heart rate - maximum absolute value greater than (>)120 beats/min, minimum absolute value less than (<)40 beats/min. Supine and standing (1 and 3 min) SBP - maximum absolute value >180 millimeters of mercury (mmHg), minimum absolute value <90 mmHg, and increase or decrease from baseline of greater than or equal to (≥)30 mmHg; supine and standing (1 and 3 min) DBP - maximum absolute value >110 mmHg, minimum absolute value <50 mmHg, and increase or decrease from baseline of ≥20 mmHg. Only those categories where at least 1 participant met the PCS criterion at least once during postbaseline duration are reported. |
Not provided
Inclusion Criteria:
Participant is in good physical health and has no clinically significant findings (excluding ET) that may impact their ability to participate in the study, as determined by the investigator, on physical examination, 12-lead electrocardiogram (ECG), or clinical laboratory tests.
Participant has a clinician-confirmed diagnosis of ET in compliance with all the following criteria:
Participant has completed the planned end of treatment (EOT) visit and was not early terminated during the planned Treatment Period in another SAGE-324 study.
Participant is willing to limit use of alcohol to 2 units per day for males and 1 unit per day for females starting at least 1 week prior to Day 1 and through the End of Study (EOS) Visit.
Participant is willing to maintain prestudy consumption of products that contain nicotine starting at least 1 week prior to Day 1 and through EOS Visit.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sage Investigational Site | Hoover | Alabama | 35244 | United States | ||
| Sage Investigational Site |
Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Not provided
Not provided
Not provided
Not provided
This was a single-arm study and all participants received SAGE-324 according to a predefined up-titration scheme as follows: 15 milligrams (mg) from Day 1 to Day 14, followed by up-titration to 30 mg from Day 15 to Day 28, then to 45 mg from Day 29 to Day 42, and then 60 mg starting on Day 43. Data were collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study.
Participants were enrolled at 29 investigative sites in the United States from 03 June 2022 to 10 September 2024.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | SAGE-324 | Participants received SAGE-324 15 mg from Day 1 to Day 14, followed by up-titration to 30 mg from Day 15 to Day 28, then to 45 mg from Day 29 to Day 42, and then 60 mg starting on Day 43, orally, once daily. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Nov 8, 2023 | Jul 15, 2025 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to 814 days |
| Number of Participants With PCS Electrocardiogram (ECG) Findings for QT Corrected According to Fridericia's Formula [QTcF]) | Number of participants with PCS postbaseline values for QTcF are categorized as follows: absolute value >450 milliseconds (msec) and ≤480msec; absolute value >480 msec and ≤500msec; absolute value >500 msec and increase from baseline >30 and ≤60 msec; increase from baseline >60 msec. Only those categories where at least 1 participant met the PCS criterion at least once during postbaseline are reported. | Up to 814 days |
| Number of Participants With PCS Laboratory Parameters | Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Number of participants with PCS laboratory values are summarized for clinical chemistry, liver function tests, hematology, and coagulation. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported. Number analyzed is the number of participants with data available for analyses for the specified category. | Up to 814 days |
| Change From Baseline in Epworth Sleepiness Scale (ESS) Score | ESS consists of 8 items where participants rate, on a 4-point scale of 0 (no chance of dozing) to 3 (high chance of dozing), their usual chances of dozing off or falling asleep while engaged in 8 different activities. ESS total score is sum of the 8 individual item scores and estimates a participant's average sleep propensity. ESS score can range from 0 to 24. ESS score ≥ 10 was used to indicate excessive daytime sleepiness. A higher score indicates more severe excessive daytime sleepiness. Baseline was defined as last non-missing measurement prior to the first dose of investigational product. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 70, 84, 112, 140, 168, 274, 365, 456, 548, 639, 730, 765, End of Treatment [EOT] (anytime, up to Day 793), End of Study [EOS] (anytime, up to Day 814) |
| Number of Participants With Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Responses | C-SSRS scale consists of baseline evaluation that assesses lifetime experience of participant with suicidal ideation & behavior, & post-baseline evaluation that focuses on suicidality since last study visit. C-SSRS included 'yes'/'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1-5, with 5 being most severe). Higher score indicated more severe symptoms. If any of assessments in suicidal behavior are 'Yes', category is considered as 'Suicidal behavior'. If any of assessments in suicidal ideation is 'Yes', but all assessments in suicidal behavior are 'No', category is considered as 'Suicidal ideation'. Baseline: any 'Yes' in any question in suicidal ideation/behavior prior to first dose of investigational product, excluding lifetime assessments. Data is reported for only those timepoints where participants had at least one 'yes' response to suicidal ideation or suicidal behavior except at Baseline. | Baseline up to Day 814 |
| Physician Withdrawal Checklist (PWC-20) Scale Total Score | PWC is based on 35-item Penn Physician Withdrawal Checklist that was developed to measure benzodiazepine and benzodiazepine-like discontinuation symptoms. PWC-20 is a shorter version of Penn Physician Withdrawal Checklist and is made up of a list of 20 symptoms (e.g., loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability) that are rated on a scale of 0 (not present) to 3 (severe). Total scores can range from 0 to 60; higher scores indicating more severe symptoms. PWC-20 assessments were conducted at EOT and EOS to monitor for presence of potential withdrawal symptoms following discontinuation of IP. EOT was defined as first available assessment after last dose of study treatment and within 1 day of last dose of study treatment. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | EOT (anytime, up to Day 793), EOS (anytime, up to Day 814) |
| Scottsdale |
| Arizona |
| 85258 |
| United States |
| Sage Investigational Site | Fountain Valley | California | 92708 | United States |
| Sage Investigational Site | Fullerton | California | 92835 | United States |
| Sage Investigational Site | Los Angeles | California | 90095 | United States |
| Sage Investigational Site | Englewood | Colorado | 80113 | United States |
| Sage Investigational Site | Boca Raton | Florida | 33486 | United States |
| Sage Investigational Site | Bradenton | Florida | 34205 | United States |
| Sage Investigational Site | Coral Springs | Florida | 33067 | United States |
| Sage Investigational Site | Hollywood | Florida | 33024 | United States |
| Sage Investigational Site | Miami | Florida | 33136 | United States |
| Sage Investigational Site | Miami | Florida | 33175 | United States |
| Sage Investigational Site | Miami | Florida | 33176 | United States |
| Sage Investigational Site | Naples | Florida | 34105 | United States |
| Sage Investigational Site | Orlando | Florida | 32803 | United States |
| Sage Investigational Site | Tampa | Florida | 33612 | United States |
| Sage Investigational Site | Atlanta | Georgia | 30329 | United States |
| Sage Investigational Site | Decatur | Georgia | 30030 | United States |
| Sage Investigational Site | Kansas City | Kansas | 66160 | United States |
| Sage Investigational Site | Lexington | Kentucky | 40509 | United States |
| Sage Investigational Site | Shreveport | Louisiana | 71105 | United States |
| Sage Investigational Site | Boston | Massachusetts | 02131 | United States |
| Sage Investigational Site | Farmington Hills | Michigan | 48334 | United States |
| Sage Investigational Site | New York | New York | 10003 | United States |
| Sage Investigational Site | New York | New York | 10032 | United States |
| Sage Investigational Site | Asheville | North Carolina | 28806 | United States |
| Sage Investigational Site | Cincinnati | Ohio | 45219 | United States |
| Sage Investigational Site | Dayton | Ohio | 45417 | United States |
| Sage Investigational Site | Tulsa | Oklahoma | 74136 | United States |
| Sage Investigational Site | Memphis | Tennessee | 38157 | United States |
| Sage Investigational Site | Austin | Texas | 78746 | United States |
| Sage Investigational Site | Fort Worth | Texas | 76104 | United States |
| Sage Investigational Site | Houston | Texas | 77030 | United States |
| Sage Investigational Site | Katy | Texas | 77450 | United States |
| Sage Investigational Site | Round Rock | Texas | 78681 | United States |
| Sage Investigational Site | West Falls Church | Virginia | 22042 | United States |
| Sage Investigational Site | Kirkland | Washington | 12039 | United States |
| Sage Investigational Site | Spokane | Washington | 99202 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
The Safety Set included all participants who were administered at least one dose of SAGE-324.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | SAGE-324 | Participants received SAGE-324 15 mg from Day 1 to Day 14, followed by up-titration to 30 mg from Day 15 to Day 28, then to 45 mg from Day 29 to Day 42, and then 60 mg starting on Day 43, orally, once daily. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) | An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the first dose of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study. | The Safety Set included all participants who were administered at least one dose of SAGE-324. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | Posted | Count of Participants | Participants | Up to 814 days |
|
|
| ||||||||||||||||||||||||||
| Secondary | Number of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements: Heart Rate, Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) | Number of participants with PCS postbaseline vital sign values are summarized for categories: supine and standing (1 and 3 minutes [min]) heart rate - maximum absolute value greater than (>)120 beats/min, minimum absolute value less than (<)40 beats/min. Supine and standing (1 and 3 min) SBP - maximum absolute value >180 millimeters of mercury (mmHg), minimum absolute value <90 mmHg, and increase or decrease from baseline of greater than or equal to (≥)30 mmHg; supine and standing (1 and 3 min) DBP - maximum absolute value >110 mmHg, minimum absolute value <50 mmHg, and increase or decrease from baseline of ≥20 mmHg. Only those categories where at least 1 participant met the PCS criterion at least once during postbaseline duration are reported. | The Safety Set included all participants who were administered at least one dose of SAGE-324. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | Posted | Count of Participants | Participants | Up to 814 days |
| ||||||||||||||||||||||||||||
| Secondary | Number of Participants With PCS Electrocardiogram (ECG) Findings for QT Corrected According to Fridericia's Formula [QTcF]) | Number of participants with PCS postbaseline values for QTcF are categorized as follows: absolute value >450 milliseconds (msec) and ≤480msec; absolute value >480 msec and ≤500msec; absolute value >500 msec and increase from baseline >30 and ≤60 msec; increase from baseline >60 msec. Only those categories where at least 1 participant met the PCS criterion at least once during postbaseline are reported. | The Safety Set included all participants who were administered at least one dose of SAGE-324. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | Posted | Count of Participants | Participants | Up to 814 days |
|
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With PCS Laboratory Parameters | Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Number of participants with PCS laboratory values are summarized for clinical chemistry, liver function tests, hematology, and coagulation. Only those categories where at least 1 participant had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported. Number analyzed is the number of participants with data available for analyses for the specified category. | The Safety Set included all participants who were administered at least one dose of SAGE-324. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | Posted | Count of Participants | Participants | Up to 814 days |
|
| |||||||||||||||||||||||||||
| Secondary | Change From Baseline in Epworth Sleepiness Scale (ESS) Score | ESS consists of 8 items where participants rate, on a 4-point scale of 0 (no chance of dozing) to 3 (high chance of dozing), their usual chances of dozing off or falling asleep while engaged in 8 different activities. ESS total score is sum of the 8 individual item scores and estimates a participant's average sleep propensity. ESS score can range from 0 to 24. ESS score ≥ 10 was used to indicate excessive daytime sleepiness. A higher score indicates more severe excessive daytime sleepiness. Baseline was defined as last non-missing measurement prior to the first dose of investigational product. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | The Safety Set included all participants who were administered at least one dose of SAGE-324. Number analyzed is the number of participants with data available for analysis at specified timepoints. | Posted | Mean | Standard Deviation | score on a scale | Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 70, 84, 112, 140, 168, 274, 365, 456, 548, 639, 730, 765, End of Treatment [EOT] (anytime, up to Day 793), End of Study [EOS] (anytime, up to Day 814) |
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Responses | C-SSRS scale consists of baseline evaluation that assesses lifetime experience of participant with suicidal ideation & behavior, & post-baseline evaluation that focuses on suicidality since last study visit. C-SSRS included 'yes'/'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1-5, with 5 being most severe). Higher score indicated more severe symptoms. If any of assessments in suicidal behavior are 'Yes', category is considered as 'Suicidal behavior'. If any of assessments in suicidal ideation is 'Yes', but all assessments in suicidal behavior are 'No', category is considered as 'Suicidal ideation'. Baseline: any 'Yes' in any question in suicidal ideation/behavior prior to first dose of investigational product, excluding lifetime assessments. Data is reported for only those timepoints where participants had at least one 'yes' response to suicidal ideation or suicidal behavior except at Baseline. | The Safety Set. Number analyzed are number of participants with data available at specified timepoint. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | Posted | Count of Participants | Participants | Baseline up to Day 814 |
| ||||||||||||||||||||||||||||
| Secondary | Physician Withdrawal Checklist (PWC-20) Scale Total Score | PWC is based on 35-item Penn Physician Withdrawal Checklist that was developed to measure benzodiazepine and benzodiazepine-like discontinuation symptoms. PWC-20 is a shorter version of Penn Physician Withdrawal Checklist and is made up of a list of 20 symptoms (e.g., loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability) that are rated on a scale of 0 (not present) to 3 (severe). Total scores can range from 0 to 60; higher scores indicating more severe symptoms. PWC-20 assessments were conducted at EOT and EOS to monitor for presence of potential withdrawal symptoms following discontinuation of IP. EOT was defined as first available assessment after last dose of study treatment and within 1 day of last dose of study treatment. All participants received SAGE-324 according to a predefined up-titration scheme. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study. | The Safety Set included all participants who were administered at least one dose of SAGE-324. Number analyzed are unique number of participants out of all the assessed participants with data available at the specified timepoint. Different participants may have contributed data for each timepoint. | Posted | Mean | Standard Deviation | score on a scale | EOT (anytime, up to Day 793), EOS (anytime, up to Day 814) |
|
Up to 814 days
The Safety Set: all participants who were administered at least one dose of SAGE-324. All participants received SAGE-324 according to a predefined up-titration scheme as follows: 15 mg from Day 1 to Day 14, followed by up-titration to 30 mg from Day 15 to Day 28, then to 45 mg from Day 29 to Day 42, and then 60 mg starting on Day 43. Data was collected and reported in single arm for each participant who started treatment as specified and either completed or discontinued study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | SAGE-324 | Participants received SAGE-324 15 mg from Day 1 to Day 14, followed by up-titration to 30 mg from Day 15 to Day 28, then to 45 mg from Day 29 to Day 42, and then 60 mg starting on Day 43, orally, once daily. | 0 | 97 | 6 | 97 | 86 | 97 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Aphasia | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
| |
| Deep vein thrombosis | Vascular disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Hypoaesthesia | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Mental status changes | Psychiatric disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Multiple injuries | Injury, poisoning and procedural complications | MedDRA 25.0 | Systematic Assessment |
| |
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Post procedural haemorrhage | Injury, poisoning and procedural complications | MedDRA 25.0 | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA 25.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Somnolence | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Balance disorder | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Cognitive disorder | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Tremor | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Abnormal dreams | Psychiatric disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Feeling abnormal | General disorders | MedDRA 25.0 | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA 25.0 | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | MedDRA 25.0 | Systematic Assessment |
|
The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Carrie Vaudreuil | Sage Therapeutics | +1-857-259-4766 | carrie.vaudreuil@sagerx.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Oct 23, 2024 | Jul 15, 2025 | SAP_001.pdf |
| ID | Term |
|---|---|
| D020329 | Essential Tremor |
| ID | Term |
|---|---|
| D009069 | Movement Disorders |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|